Podcasts about thromboprophylaxis

Listen to Andrew Duckworth, Daniel Horner, and Xavier L. Griffin discuss the paper 'Thromboprophylaxis for the trauma and orthopaedic surgeon' published in the April 2024 issue of The Bone & Joint Journal.Click here to read the paper.Find out as soon as the next episode is live by following us on X (Twitter), Instagram, LinkedIn, Tik Tok or Facebook!

CME credits: 1.75 Valid until: 29-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-time-vt-edwards-management-of-extended-thromboprophylaxis-in-the-medically-ill/24229/ Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the guidelines that can be used daily to help with the management of VTE in daily practice.

Welcome to the latest episode of Cardiology Digest, where we dive into the pressing questions of today's medical research. Here's a glimpse of what's to come:   STUDY #1: Have you ever wondered about the optimal timing for introducing DOACs (direct-acting oral anticoagulants) after strokes due to atrial fibrillation? This New England Journal of Medicine study dives into the potential advantages of early DOAC introduction. You might be surprised at the rates of symptomatic intracranial hemorrhage. But remember, patient profiles vary—for example, what works for those with mild neurologic deficits might not hold true for everyone. Fischer, U, Koga, M, Strbian, D, et al. 2023. Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med. 26: 2411–2421. (https://doi.org/10.1056/NEJMoa2303048)   STUDY #2: Next, we'll take a look at the curious case of rising hematocrit in certain chronic kidney disease patients who have anemia and were treated with SGLT-2 inhibitors. Did they have a genuine improvement in anemia or was it merely an illusion? SGLT-2 inhibitors are the focal point, and we'll dissect their multifaceted effects that may be at play here.  Koshino, A, Schechter, M, Chertow, GM, et al. 2023. Dapagliflozin and anemia in patients with chronic kidney disease. NEJM Evid.  6. (https://doi.org/10.1056/EVIDoa2300049)   STUDY #3: Hospitalization due to COVID-19 has presented a conundrum regarding post-discharge thromboprophylaxis. With the pandemic making such profound impacts on global health, it's crucial to address these concerns. See how new findings align with prior observational studies, and where rivaroxaban fits into all of this. Wang, TY,  Wahed, AS, Morris, A, et al. 2023. Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization. Ann Intern Med. 4: 515–523. (https://doi.org/10.7326/M22-3350)   STUDY #4: Cholesterol management remains pivotal in cardiac care. But the question our fourth study poses is this: do age differences impact the effectiveness of statins, particularly in lowering LDL cholesterol? A dive into this study could reshape perceptions on dosage recommendations for certain patient demographics. Corn, G, Melbye, M, Hlatky, MA, et al. 2023. Association between age and low-density lipoprotein cholesterol response to statins: A Danish nationwide cohort study. Ann Intern Med. 8: 1017–1026. (https://doi.org/10.7326/M22-2643)   So, arm yourself with your favorite beverage and comfy earphones, and join us in uncovering the gems these studies hold. The revelations might just change the way you see these medications and treatments!

Editor’s Choice Paper: Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis? Editorial: Universal thromboprophylaxis in ovarian cancer patients before and after surgery? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Amanika Kumar, MD, Mayo Clinic Laura Havrilesky, MD, Duke University

Editor’s Choice Paper: Incidence of venous thromboembolism in patients with advanced stage ovarian cancer undergoing neoadjuvant chemotherapy: Is it time for thromboprophylaxis? Editorial: Universal thromboprophylaxis in ovarian cancer patients before and after surgery? Hosted by:David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic OncologyFeaturing:Amanika Kumar, MD, Mayo Clinic Laura Havrilesky, MD, Duke University

Commentary by Dr. Candice Silversides

Drs. Conor Kleweno and Bob O'Toole discuss this landmark paper published in the New England Journal of Medicine.   For additional educational resources visit www.ota.org Looking for CME? OTA Podcast CME only on the free ConveyMED Podcast App: Apple Store click here Google Play click here

CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/primary-thromboprophylaxis-patient-high-risk-vte-who-receiving-systemic-anticancer-therapy/14727/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of multiple options to appropriately treat and manage CAT, thrombosis is a complication that HCPs are not recognizing early enough; plus, there is a lack of awareness of new CAT management clinical data. While the morbidity and mortality of VTE in patients with cancer remain high, unfortunately, the management of it does not take the same priority. While recommendations suggest an individualized approach to managing these patients, adoption into clinical practice lags. Published guidelines and clinical trial data do not necessarily align with real-world practice and prescribing behaviors. As a result, many existing protocols for CAT management require updates, as new guidance is warranted. This program focuses on managing cancer-associated venous thromboembolic disease, with a special emphasis on translating real-world data and evidence-based medicine, including recent clinical guidelines, into clinical practice.

The NACE Journal Club with Dr. Neil Skolnik, is a new series of episodes that provide review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture Major Extremity Trauma Research Consortium (METRC), N Engl J Med 2023; 388:203-213Guest: Marissa Norden, DO,  2nd year resident Jefferson Health AbingtonLong-term Weight Training and Mortality in U.S. Male Health Professionals With and Without Type 2 Diabetes Dong Hoon Lee et.al.;Diabetes Care 2023;46(1):138–148Guest: Matt Rubin, MD, attending physician at Main Line Health Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low- Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease Ann Intern Med. 2023 Jan;176(1):I18. doi: 10.7326/P22-0022. Epub 2022 Dec 13. Guest: Gabriella Petrongolo, DO, 2nd year resident Jefferson Health AbingtonAssociations of Physical Inactivity and COVID-19 Outcomes - American Journal of Preventive Medicine  Young DR, Sallis JF, Baecker A, Cohen DA, Nau CL, Smith GN, Sallis RE.;Am J Prev Med. 2022 Dec 10:S0749-3797(22)00526-8. doi: 10.1016/j.amepre.2022.10.007. Epub ahead of print.           Guest: Alex Fierstein, DO, 3rd year resident Jefferson Health AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Dr. Ebell and Dr. Wilkes discuss the POEM titled ' Twice-daily low-dose aspirin is similar to enoxaparin for thromboprophylaxis after inpatient treatment for fracture (PREVENT CLOT) '

Dr. Ebell and Dr. Wilkes discuss the POEM titled ' Thromboprophylaxis after discharge improves clinical outcomes for certain high-risk patients hospitalized with COVID-19 (MICHELLE) '

Reviewing the data and guidelines to provide anticoagulation or VTE prophylaxis to our patients with COVID-19. Show Notes: https://eddyjoemd.com/anticoagulation-covid/ Although great care has been taken to ensure that the information in this podcast are accurate, eddyjoe, LLC shall not be held responsible or in any way liable for the continued accuracy of the information, or for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Website: www.eddyjoemd.com Instagram: www.instagram.com/eddyjoemd Twitter: www.twitter.com/eddyjoemd Facebook: www.facebook.com/eddyjoemd Podcast: https://anchor.fm/eddyjoemd My Amazon store for resources you may find helpful: www.amazon.com/shop/eddyjoemd Citation: Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Iaccarino J, Jimenez D, LeGal G, Rali P, Wells P, Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report, CHEST (2022), doi:https://doi.org/10.1016/j.chest.2022.02.006. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/eddyjoemd/support

Today we are joined by Dr. Brian Locke to talk about the newest big trial on IV fluids in critically ill patients and a meta-analysis that looks at all the similar trials. Is this question finally settled?We also look at PICC lines vs midlines, IV L-ornithine L-aspartate in acute treatment of hepatic encephalopathy, a new ward-based program for delirium prevention in older inpatients, post-discharge thromboprophylaxis for high risk COVID patients, and whether mindfulness training can help burnout in residents.Balanced Multielectrolyte Solution vs Normal Saline in Critically Ill Patients (PLUS)Balanced Crystalloid vs Normal Saline Meta-analysisPICC lines vs MidlinesApixaban vs Rivaroxaban for Recurrent VTE LOLA for Hepatic EncephalopathyEat-Walk-Engage in Older Inpatients (CHERISH)Rivaroxaban for Post-discharge Prophylaxis in High Risk COVID patients (MICHELLE)Mindfulness Training and BurnoutMusic from Uppbeat (free for Creators!):https://uppbeat.io/t/soundroll/dopeLicense code: NP8HLP5WKGKXFW2R

Preventing thromboembolic events in COVID-19

Interview with Alex C. Spyropoulos, author of Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

In this episode, we discuss new evidence about how many obstetric patients benefit from thromboprophylaxis. Then we discuss techniques for Cesareans involving impacted fetal heads. Also, we discuss the guidelines for aspirin to prevent preeclampsia and the link between autism and epidurals. 

Interview with Alex C. Spyropoulos, author of Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

Interview with Alex C. Spyropoulos, author of Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial

This week Kate, Mark, Henry and John (he's back!) discuss dexamethasone after major non-cardiac surgery, topical terbinafine for onychomycosis, thromboprophylaxis during knee replacement, and mRNA COVID vaccine adverse events

Recently published RCTs and various guidelines have given us conflicting results w.r.t optimal dose of thromboprophylaxis in patients with COVID-19. In this episode, we dive deeper into the available evidence on this topic and suggest the rational approach in selecting the dose of thromboprophylaxis in COVID-19 patients.

Today we are doing double duty: podcasting and parenting.  Fortunately our babies were well-behaved.  We talk about three trials for semaglutide and weight loss and a new 4 level pre-test probability rule for diagnosing PE.  We also talk about a retrospective study of cefazolin vs nafcillin for epidural abscess, a ferritin/procalcitonin ratio for differentiating bacterial from COVID pneumonia, and a new randomized controlled trial of intermediate thromboprophylaxis for ICU patients with COVID19.  Check it out! Semaglutide for Weight Loss (STEP 1)Semaglutide for Weight Loss in Diabetics (STEP 2)Semaglutide + Intensive Calorie Restriction for Weight Loss (STEP 3)4PEPS for Pulmonary EmbolismNafcillin vs Cefazolin for Epidural AbscessFerritin/Procalcitonin Ratio for COVID-19 vs Bacterial PneumoniaIntermediate Thromboprophylaxis for COVID-19 (INSPIRATION) Music from https://filmmusic.io"Sneaky Snitch" by Kevin MacLeod (https://incompetech.com)License: CC BY (http://creativecommons.org/licenses/by/4.0/) Hall of the Mountain King Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 3.0 Licensehttp://creativecommons.org/licenses/by/3.0/

This week, we will discuss a potpourri of COVID studies: a large propensity score matched study of thromboprophylaxis in hospitalized patients, novel use of colchicine for COVID-19, and mortality associated with mutant SARS-CoV-2 strains.

Drs Sheean and Athiviraham discuss Pharmacologic Thromboprophylaxis Other Than Aspirin Is Associated with Increased Risk for Procedural Intervention for Arthrofibrosis After ACL Reconstruction.

Drs Sheean and Athiviraham discuss Pharmacologic Thromboprophylaxis Other Than Aspirin Is Associated with Increased Risk for Procedural Intervention for Arthrofibrosis After ACL Reconstruction.

Welcome back to the VTE Dublin Podcast where you’ll find all the recent talks from the VTE Dublin Conference. Be sure to subscribe to the VTE Dublin Podcast Thromboprophylaxis for lower limb immobilisation after injury (TiLLI): Systematic review and economic evaluation Prof. Dan Horner | Professor of the Royal College of Emergency Medicine | Consultant […]

Welcome back to the VTE Dublin Podcast where you’ll find all the recent talks from the VTE Dublin Conference. Be sure to subscribe to the VTE Dublin Podcast Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting Prof. Suzanne Cannegieter | Department of Clinical Epidemiology | Leiden University Medical Centre | Leiden | the Netherlands Video: Audio: […]

Welcome back to the VTE Dublin Podcast where you’ll find all the recent talks from the VTE Dublin Conference. Be sure to subscribe to the VTE Dublin Podcast VTE risk assessment and thromboprophylaxis: a state of the art review of current scientific progress Dr Niamh O’Connell | Consultant Haematologist | National Coagulation Centre | St […]

COVID-19 can have a negative impact on systems throughout the body, beyond just the lungs, according to a review published in Nature Medicine. Two authors of the review joined host David H. Henry, MD, to discuss their article, “Extrapulmonary manifestations of COVID-19.”  Aakriti Gupta, MD, of Columbia University Irving Medical Center, and Kartik Sehgal, MD, of Dana Farber Cancer Institute, discussed: ACE2, the entry receptor for SARS-CoV-2 Neurologic and gastrointestinal manifestations of COVID-19 Mechanisms of coagulation and thromboprophylaxis COVID-19 in cancer patients The impact of quarantine on cardiology patients The lasting effects of COVID-19 and the need for follow-up The importance of international collaboration for clinical trials. For more details on how COVID-19 can affect the body, see the full review in Nature Medicine: Gupta A. et al. Nat Med. 2020 Jul;26(7):1017-1032.  Disclosures: Dr. Henry and Dr. Sehgal have no financial disclosures relevant to this episode. Dr. Gupta disclosed relationships with the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation, the Ben C. Martin Law Firm for work related to the Cook inferior vena cava filter litigation, Edward Lifesciences, and Heartbeat Health. * * *  For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd

Simon Carley, Associate Editor of EMJ, talks through his highlights of the January 2020 edition of the Emergency Medicine Journal. Read the primary survey here - emj.bmj.com/content/37/1 Details of the papers mentioned in this podcast can be found below: Comparison of four decision aids for the early diagnosis of acute coronary syndromes in the emergency department https://emj.bmj.com/content/37/1/8 The incidence of airway haemorrhage in manual versus mechanical cardiopulmonary resuscitation https://emj.bmj.com/content/37/1/14 Epidemiology of adolescent trauma in England: a review of TARN data 2008–2017 - https://emj.bmj.com/content/37/1/25 Blood Glucose Reduction in Patients Treated with Insulin and Dextrose for Hyperkalemia - https://emj.bmj.com/content/37/1/31 No rest for the weary: A cross-sectional study comparing patients sleep in the emergency department to those on the ward https://emj.bmj.com/content/37/1/42 Thromboprophylaxis in Lower Limb Immobilisation after Injury (TiLLI) https://emj.bmj.com/content/37/1/36 Emergency Medicine: let’s feed the good wolf - https://emj.bmj.com/content/37/1/52 Read the full January issue here - https://emj.bmj.com/content/37/1

 Alok Khorana, MD, of the Cleveland Clinic joins Blood & Cancer host David H. Henry, MD, of Pennsylvania Hospital, Philadelphia, to break down the latest recommendations from the American Society of Clinical Oncology on venous thromboembolism (VTE) prophylaxis in cancer patients. Plus, in Clinical Correlation, Ilana Yurkiewicz, MD, of Stanford (Calif.) University, shares her answer to a frequent question from cancer patients: What should I eat? This Week in Oncology What is the role of thromboprophylaxis in patients with cancer in the outpatient setting?  Key change in ASCO recommendations: Thromboprophylaxis with apixaban, rivaroxaban, or low-molecular-weight heparin (LMWH) may be offered to select high-risk outpatients with cancer. Prophylactic anticoagulation should not be given to every patient with malignancy. Khorana score predicts the venous thromboembolism in patients with malignancy. Influenced by type of malignancy, hemoglobin, platelet count, leukocyte count, and BMI. High risk = Khorana score of 2 or higher may be offered prophylaxis. Patients with pancreatic cancer and gastric cancer are particularly coagulopathic. Does the presence of a CNS lesion(s) preclude anticoagulation for a DVT/PE? All CNS lesions have a risk of hemorrhage. A CNS lesion hemorrhage is not significantly greater when anticoagulated Among high-risk cancer patients who undergo surgery, is there a role for postoperative prophylaxis with LMWH? Data show a persistent risk of VTE up to 4 weeks following abdominal/pelvic surgery.   Show notes by Emily Bryer, DO, resident in the department of internal medicine, University of Pennsylvania, Philadelphia.   References: Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update ascopubs.org/doi/pdf/10.1200/JCO.19.01461 Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer nejm.org/doi/full/10.1056/NEJMoa1814630 Apixaban to prevent venous thromboembolism in patients with cancer nejm.org/doi/full/10.1056/NEJMoa1814468   For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc Ilana Yurkiewicz on Twitter: @ilanayurkiewicz  

In this week's episode we critique the statistics of the recent trial "Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study" that was published in The Lancet Oncology. Then, with Dr. Sven Olson of OHSU, we break down the two papers published in NEJM on thromboprophylaxis with direct oral anticoagulants (DOACs) for patients with cancer: "Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer" and "Apixaban to Prevent Venous Thromboembolism in Patients with Cancer". BILCAP: www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30915-X Rivaroxaban: doi.org/10.1056/NEJMoa1814630 Apixaban: doi.org/10.1056/NEJMoa1814468 Back us on Patreon! www.patreon.com/plenarysession

Thieme Verlagamrican perinatly0:00Wed, 19 Dec 2018 00:00:00 GMT

Thieme Verlagamrican perinatly0:00Wed, 19 Dec 2018 00:00:00 GMT

Deputy Editor-in-Chief, Dr John Thorp, discusses a paper published in the August issue of BJOG. The original Editor's Choice is available at https://obgyn.onlinelibrary.wiley.com/doi/10.1111/1471-0528.14886.

Prof Khorana talks to ecancertv at ASH 2015 about a randomised trial looking at the outpatient use of dalteparin for the prevention of thrombosis in cancer patients at high risk of venous thromboembolism (VTE). Several years ago Dr Khorana and colleagues developed an algorithm for assessing how likely patients with cancer were to develop VTE while being treated with chemotherapy. This takes into account several factors such as the site of the cancer, the platelet and leukocyte counts before chemotherapy is given, the level of haemoglobin and the patient’s body mass index. In the current trial, patients with a high risk for VTE (Khorana score ≥3) who were initiating a new systemic chemotherapy regimen were screened for VTE, If negative for VTE, patients were randomised to either self-inject the low molecular weight heparin dalteparin daily or to no prophylactic anticoagulation for 12 weeks. Thromboprophylaxis versus no thromboprophylaxis was associated with a non-significant reduced risk of VTE and rates of major bleeding and overall survival were similar. There was an increased risk of clinically relevant bleeding, but the study was underpowered. There is a validated risk assessment tool and it can be used to find patients at the highest risk that may benefit from anticoagulation with self-injected low-molecular-weight heparin Dr Khorana observes.

Thromboprophylaxis in Pregnancy with Christopher Ciliberto

A Journal Club discussion between pharmacists and pharmacy students regarding the article Rivaroxaban for thromboprophylaxis in Acutely Ill Medical Patients

This podcast covers the JBJS issue for November 2009. Featured are articles covering Predisposing Factors for Recurrent Shoulder Dislocation After Arthroscopic Treatment; Comparison of the Clinical Results of Three Posterior Cruciate Ligament Reconstruction Techniques; Bilateral Low-Energy Simultaneous or Sequential Femoral Fractures in Patients on Long-Term Alendronate Therapy; recorded commentary by Dr. Lane; Thromboprophylaxis in Patients with Acute Spinal Injuries: An Evidence-Based Analysis; Extracorporeal Shock-Wave Therapy Compared with Surgery for Hypertrophic Long-Bone Nonunions.

This podcast covers the JBJS issue for November 2009. Featured are articles covering Predisposing Factors for Recurrent Shoulder Dislocation After Arthroscopic Treatment; Comparison of the Clinical Results of Three Posterior Cruciate Ligament Reconstruction Techniques; Bilateral Low-Energy Simultaneous or Sequential Femoral Fractures in Patients on Long-Term Alendronate Therapy; recorded commentary by Dr. Lane; Thromboprophylaxis in Patients with Acute Spinal Injuries: An Evidence-Based Analysis; Extracorporeal Shock-Wave Therapy Compared with Surgery for Hypertrophic Long-Bone Nonunions.

Patients with cancer are at increased risk of venous thromboembolism (VTE) compared with patients without cancer. This results from both the prothrombotic effects of the cancer itself and iatrogenic factors, such as chemotherapy, radiotherapy, indwelling central venous devices and surgery, that further increase the risk of VTE. Although cancer-associated thrombosis remains an important cause of morbidity and mortality, it is often underdiagnosed and undertreated. However, evidence is accumulating to support the use of low-molecular-weight heparins (LMWHs) in the secondary prevention of VTE in patients with cancer. Not only have LMWHs been shown to be at least as effective as coumarin derivatives in this setting, but they have a lower incidence of complications, including bleeding, and are not associated with the practical problems of warfarin therapy. Furthermore, a growing number of studies indicate that LMWHs may improve survival among patients with cancer due to a possible antitumor effect. Current evidence suggests that LMWHs should increasingly be considered for the long-term management of VTE in patients with cancer.